Table 2 Anti-malarial treatment prescribed
Drug group/treatment | N | % |
|---|---|---|
1 st line therapy (ART-AQ) | 1,217 | 43.0 |
Combination therapy – other ACT | 418 | 14.8 |
DHA+AQ | 240 | 8.5 |
Artemether+AQ | 77 | 2.7 |
Artemether+lumefantrine | 58 | 2.1 |
DHA+pyrimethamine-sulphametopirazine | 13 | 0.5 |
Artesunate+SP | 12 | 0.4 |
DHA+SP | 6 | 0.2 |
DHA+chloroquine | 5 | 0.2 |
Artesunate+chloroquine | 3 | 0.1 |
Artemether+pyrimethamine-sulphametopirazine | 1 | 0.04 |
Artemether+quinine | 1 | 0.04 |
Artesunate+ quinine | 1 | 0.04 |
DHA+artemether+lumefantrine | 1 | 0.04 |
Monotherapy – artemisinin based | 936 | 33.1 |
DHA | 577 | 20.4 |
Artesunate | 293 | 10.4 |
Artemether | 55 | 1.9 |
Artesunate/artemether | 10 | 0.4 |
Artemether/DHA | 1 | 0.04 |
Monotherapy – non-artemisinin | 260 | 9.2 |
Amodiaquine | 133 | 4.7 |
SP | 78 | 2.8 |
Pyrimethamine-sulphametopirazine | 32 | 1.1 |
Chloroquine | 14 | 0.5 |
Quinine | 3 | 0.1 |
Total | 2,831 |